| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 37 | 2026 | 118 | 8.740 |
Why?
|
| Phenylthiohydantoin | 25 | 2026 | 57 | 4.100 |
Why?
|
| Prostatic Neoplasms | 38 | 2026 | 1841 | 3.850 |
Why?
|
| Benzamides | 25 | 2026 | 260 | 3.420 |
Why?
|
| Nitriles | 25 | 2026 | 171 | 3.090 |
Why?
|
| Androstenes | 14 | 2024 | 41 | 2.680 |
Why?
|
| Receptors, Glucocorticoid | 7 | 2024 | 145 | 2.270 |
Why?
|
| Androgen Antagonists | 18 | 2026 | 157 | 1.970 |
Why?
|
| Receptors, Androgen | 14 | 2024 | 125 | 1.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2026 | 2660 | 1.600 |
Why?
|
| Neoplasm Metastasis | 25 | 2026 | 1090 | 1.340 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2024 | 74 | 1.150 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 2379 | 1.050 |
Why?
|
| Male | 77 | 2026 | 47195 | 0.900 |
Why?
|
| Androgen Receptor Antagonists | 6 | 2024 | 20 | 0.890 |
Why?
|
| Prostate-Specific Antigen | 10 | 2026 | 356 | 0.790 |
Why?
|
| Food-Drug Interactions | 2 | 2014 | 19 | 0.780 |
Why?
|
| Sulfonamides | 5 | 2019 | 351 | 0.770 |
Why?
|
| Aged, 80 and over | 29 | 2026 | 7409 | 0.710 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 639 | 0.680 |
Why?
|
| Aged | 46 | 2026 | 21824 | 0.670 |
Why?
|
| Humans | 84 | 2026 | 98223 | 0.650 |
Why?
|
| Testosterone | 4 | 2021 | 265 | 0.610 |
Why?
|
| Orchiectomy | 4 | 2018 | 64 | 0.570 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 237 | 0.570 |
Why?
|
| Middle Aged | 41 | 2026 | 29494 | 0.560 |
Why?
|
| Quality of Life | 6 | 2024 | 1897 | 0.560 |
Why?
|
| Prospective Studies | 14 | 2025 | 4815 | 0.550 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 402 | 0.550 |
Why?
|
| Ascites | 1 | 2018 | 55 | 0.530 |
Why?
|
| Pyrimidines | 5 | 2019 | 414 | 0.530 |
Why?
|
| Food | 1 | 2018 | 93 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1395 | 0.520 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 304 | 0.510 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 73 | 0.490 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2026 | 7 | 0.490 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 201 | 0.480 |
Why?
|
| Prednisone | 5 | 2026 | 251 | 0.470 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2023 | 30 | 0.470 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 2894 | 0.460 |
Why?
|
| Treatment Outcome | 20 | 2026 | 9750 | 0.420 |
Why?
|
| Neoplasms | 7 | 2025 | 3348 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 670 | 0.410 |
Why?
|
| Disease Progression | 7 | 2020 | 1612 | 0.410 |
Why?
|
| Immediate-Early Proteins | 2 | 2014 | 160 | 0.400 |
Why?
|
| Patient Safety | 4 | 2019 | 234 | 0.400 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 116 | 0.400 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 61 | 0.400 |
Why?
|
| Dietary Fats | 1 | 2014 | 135 | 0.390 |
Why?
|
| Food Labeling | 1 | 2012 | 7 | 0.380 |
Why?
|
| Indoles | 1 | 2014 | 334 | 0.360 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 100 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1098 | 0.340 |
Why?
|
| Kidney Neoplasms | 3 | 2025 | 556 | 0.330 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 68 | 0.330 |
Why?
|
| Melanoma | 1 | 2014 | 524 | 0.300 |
Why?
|
| Antigens, Surface | 2 | 2026 | 100 | 0.300 |
Why?
|
| Mice, Nude | 4 | 2017 | 830 | 0.290 |
Why?
|
| Radioisotopes | 2 | 2026 | 41 | 0.290 |
Why?
|
| Cell Survival | 3 | 2017 | 1016 | 0.290 |
Why?
|
| Signal Transduction | 9 | 2024 | 3627 | 0.290 |
Why?
|
| Mifepristone | 2 | 2022 | 56 | 0.270 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2025 | 384 | 0.270 |
Why?
|
| Hormones | 3 | 2022 | 138 | 0.260 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 89 | 0.250 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2026 | 1 | 0.250 |
Why?
|
| Lutetium | 1 | 2026 | 4 | 0.250 |
Why?
|
| Research Design | 2 | 2026 | 650 | 0.250 |
Why?
|
| Dipeptides | 1 | 2026 | 41 | 0.240 |
Why?
|
| Iodine Radioisotopes | 1 | 2026 | 145 | 0.230 |
Why?
|
| Abiraterone Acetate | 3 | 2026 | 14 | 0.230 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3279 | 0.230 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1770 | 0.230 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 568 | 0.220 |
Why?
|
| Androgens | 3 | 2023 | 164 | 0.220 |
Why?
|
| Patient Portals | 1 | 2025 | 36 | 0.210 |
Why?
|
| Neutropenia | 2 | 2023 | 211 | 0.210 |
Why?
|
| Combined Modality Therapy | 6 | 2026 | 1751 | 0.210 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.210 |
Why?
|
| Phthalazines | 1 | 2024 | 59 | 0.210 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.200 |
Why?
|
| CDC2 Protein Kinase | 1 | 2023 | 46 | 0.190 |
Why?
|
| Radium | 1 | 2023 | 7 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1213 | 0.190 |
Why?
|
| Piperazines | 1 | 2024 | 307 | 0.180 |
Why?
|
| Capecitabine | 2 | 2024 | 103 | 0.180 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 126 | 0.180 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1194 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2026 | 1126 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 244 | 0.180 |
Why?
|
| Dehydroepiandrosterone | 2 | 2020 | 47 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2024 | 262 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 160 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2025 | 423 | 0.170 |
Why?
|
| Frailty | 1 | 2023 | 103 | 0.170 |
Why?
|
| Prostatectomy | 2 | 2026 | 491 | 0.170 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 22 | 0.170 |
Why?
|
| Pharmacogenetics | 1 | 2025 | 473 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1790 | 0.170 |
Why?
|
| Radiosurgery | 1 | 2025 | 352 | 0.170 |
Why?
|
| Castration | 2 | 2012 | 32 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 419 | 0.160 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2020 | 16 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2021 | 100 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1946 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2024 | 371 | 0.160 |
Why?
|
| Adult | 15 | 2025 | 29548 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2025 | 734 | 0.150 |
Why?
|
| Double-Blind Method | 5 | 2025 | 1787 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2021 | 152 | 0.150 |
Why?
|
| Organic Chemicals | 1 | 2019 | 38 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 417 | 0.150 |
Why?
|
| Boronic Acids | 1 | 2019 | 56 | 0.150 |
Why?
|
| Oxidoreductases | 1 | 2019 | 112 | 0.150 |
Why?
|
| Taxoids | 2 | 2016 | 127 | 0.140 |
Why?
|
| Animals | 8 | 2024 | 28950 | 0.140 |
Why?
|
| Pyridones | 1 | 2019 | 75 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 15 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 15 | 0.140 |
Why?
|
| Azepines | 1 | 2018 | 29 | 0.140 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 41 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2019 | 139 | 0.140 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2018 | 20 | 0.140 |
Why?
|
| Singapore | 1 | 2018 | 14 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 48 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 316 | 0.140 |
Why?
|
| United States | 6 | 2020 | 8252 | 0.140 |
Why?
|
| Recurrence | 2 | 2019 | 1261 | 0.140 |
Why?
|
| Indazoles | 4 | 2023 | 63 | 0.130 |
Why?
|
| Quinolines | 1 | 2018 | 97 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 82 | 0.130 |
Why?
|
| Fasting | 1 | 2018 | 166 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 642 | 0.130 |
Why?
|
| Female | 12 | 2025 | 51685 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 108 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 246 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 336 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2021 | 817 | 0.120 |
Why?
|
| Mice | 6 | 2024 | 12718 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 199 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 478 | 0.120 |
Why?
|
| Quinolones | 1 | 2016 | 57 | 0.120 |
Why?
|
| Survival Rate | 4 | 2026 | 2050 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 135 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 338 | 0.120 |
Why?
|
| Prostate | 4 | 2025 | 434 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 557 | 0.120 |
Why?
|
| Benzodioxoles | 1 | 2015 | 15 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 889 | 0.110 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2014 | 1 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1539 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 265 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 281 | 0.100 |
Why?
|
| Quinazolines | 1 | 2015 | 221 | 0.100 |
Why?
|
| Metribolone | 1 | 2014 | 6 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 159 | 0.100 |
Why?
|
| Benzoates | 1 | 2014 | 34 | 0.100 |
Why?
|
| Proteins | 1 | 2019 | 803 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2014 | 93 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2014 | 273 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 701 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 4126 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 112 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 721 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 388 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 408 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 303 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 435 | 0.090 |
Why?
|
| Hospitalization | 1 | 2018 | 986 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1133 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2018 | 1717 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2014 | 318 | 0.090 |
Why?
|
| Precision Medicine | 3 | 2025 | 501 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2026 | 2598 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2018 | 826 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2014 | 718 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2026 | 2085 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 35 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 4041 | 0.080 |
Why?
|
| G1 Phase | 1 | 2011 | 66 | 0.080 |
Why?
|
| Decision Making | 2 | 2014 | 689 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2014 | 1528 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 156 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2025 | 168 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2011 | 330 | 0.080 |
Why?
|
| Chicago | 3 | 2025 | 1519 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 448 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1784 | 0.070 |
Why?
|
| Nausea | 2 | 2019 | 94 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 66 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2019 | 290 | 0.070 |
Why?
|
| Time Factors | 3 | 2026 | 5573 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2009 | 53 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 554 | 0.070 |
Why?
|
| Geriatric Assessment | 2 | 2023 | 193 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1816 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2026 | 4 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2020 | 0.060 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2025 | 54 | 0.050 |
Why?
|
| Age Factors | 2 | 2023 | 1972 | 0.050 |
Why?
|
| Rats | 1 | 2011 | 4073 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2026 | 206 | 0.050 |
Why?
|
| CpG Islands | 1 | 2025 | 177 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 65 | 0.050 |
Why?
|
| Leuprolide | 1 | 2024 | 34 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3611 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2025 | 119 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1033 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2789 | 0.050 |
Why?
|
| Scandium | 1 | 2023 | 4 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2024 | 380 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 178 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 3217 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2068 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 222 | 0.050 |
Why?
|
| Patient Participation | 1 | 2025 | 250 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 11031 | 0.050 |
Why?
|
| Cystectomy | 1 | 2024 | 125 | 0.050 |
Why?
|
| DNA Repair | 1 | 2024 | 363 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 16 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 970 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 16 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 37 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 583 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2022 | 54 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 2001 | 18 | 0.040 |
Why?
|
| Cisplatin | 1 | 2024 | 578 | 0.040 |
Why?
|
| Purines | 1 | 2022 | 96 | 0.040 |
Why?
|
| Tissue Extracts | 1 | 2021 | 24 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2022 | 51 | 0.040 |
Why?
|
| Piperidines | 1 | 2023 | 175 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2021 | 48 | 0.040 |
Why?
|
| Keratins | 1 | 2021 | 62 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2021 | 50 | 0.040 |
Why?
|
| Neurosecretory Systems | 1 | 2021 | 36 | 0.040 |
Why?
|
| Cell Count | 1 | 2021 | 195 | 0.040 |
Why?
|
| Glycolysis | 1 | 2022 | 198 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 47 | 0.040 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2001 | 117 | 0.040 |
Why?
|
| Prescription Drugs | 1 | 2021 | 42 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2021 | 239 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 587 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 394 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 346 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 595 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 994 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2021 | 461 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 168 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 109 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 314 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 304 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 525 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 368 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 822 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2467 | 0.030 |
Why?
|
| Bradycardia | 1 | 2018 | 51 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2019 | 303 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 836 | 0.030 |
Why?
|
| Kinetics | 1 | 2020 | 1477 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 648 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 365 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 906 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1391 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 758 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 6269 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 822 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 675 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ketoconazole | 1 | 2014 | 23 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 552 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 106 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 145 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 139 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1557 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2653 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1417 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 159 | 0.020 |
Why?
|
| Cause of Death | 1 | 2014 | 278 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 779 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 214 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 4408 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 85 | 0.020 |
Why?
|
| Kallikreins | 1 | 2012 | 47 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3030 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 195 | 0.020 |
Why?
|
| United States Department of Defense | 1 | 2011 | 4 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 743 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 921 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 388 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 1013 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 180 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 166 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 187 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1275 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 245 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 867 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 676 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 710 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 419 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 721 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 750 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 992 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 123 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2054 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 602 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 258 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 690 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 7556 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 519 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 10127 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 474 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 69 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 2001 | 125 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 983 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2001 | 358 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 720 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 3266 | 0.010 |
Why?
|